However, the nucleic acid testing results are subject to many factors, including the specimen site, type, quality, and patients’ condition, and sample storage. Therefore, rapid diagnosis and specific therapy for COVID-19 are urgently needed.Ĭurrently, the diagnosis of COVID-19 is mainly based on testing SARS-CoV-2 RNA load using quantitative real-time polymerase chain reaction (RT-PCR) 5. Over 100,000 confirmed cases were reported daily, creating major challenges for public health and medical services around the world. The high infection rate of SARS-CoV-2 leads to its rapid spread 4. As of August 19, 2020, a total of 21,938,171 confirmed cases were reported, of which 775,581 patients died. Our study provides important information for COVID-19 diagnosis, treatment, and vaccine development.Ĭoronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is spreading in more than 210 countries and territories globally 1, 2, 3. Patients with low antibody levels on discharge might thereby have a high chance of being tested positive for SARS-CoV-2 RNA after recovery. Lower S-, RBD-, and N-specific IgG levels are associated with a lower lymphocyte percentage, higher neutrophil percentage, and a longer duration of viral shedding. In addition, the S- and RBD-specific IgG levels are 2-fold higher in the recovered patients who are SARS-CoV-2 RNA negative than those who are RNA positive. The RBD-specific IgG levels are 4-fold higher in older patients than in younger patients during hospitalization. The generation of S-, RBD-, and N-specific IgG occurs one week later in patients with severe/critical COVID-19 compared to patients with mild/moderate disease, while S- and RBD-specific IgG levels are 1.5-fold higher in severe/critical patients during hospitalization. Here we analyze the laboratory findings of 1,850 patients to describe the dynamic changes of the total antibody, spike protein (S)-, receptor-binding domain (RBD)-, and nucleoprotein (N)-specific immunoglobulin M (IgM) and G (IgG) levels during SARS-CoV-2 infection and recovery. Deciphering the dynamic changes in antibodies against SARS-CoV-2 is essential for understanding the immune response in COVID-19 patients.
0 Comments
Leave a Reply. |